title: Behavioral and neuropsychiatric outcomes in Alzheimer's disease.
abstract: Behavioral and psychological symptoms of dementia pose significant challenges in the management of patients with Alzheimer's disease. Neuropsychiatric symptoms are associated with cognitive decline, highly impaired activities of daily living, and frontal lobe pathology. Moreover, behavioral and psychological symptoms can diminish patient quality of life, increase caregiver distress, and accelerate nursing home placement. Although these symptoms are often associated with the later stages of Alzheimer's disease, a high percentage of individuals with mild cognitive impairment or mild Alzheimer's report symptoms as well. This article provides an overview of behavioral and neuropsychiatric symptoms associated with Alzheimer's disease and discusses nonpharmacologic and pharmacologic approaches to the management of such symptoms. For patients with severe behavioral and psychological symptoms of dementia, psychotropic agents may be warranted, whereas approved therapies for Alzheimer's, including cholinesterase inhibitors and the N-methyl-d-aspartate receptor antagonist memantine, may be appropriate in less severe cases.
authors.affiliation: Alzheimer's Disease Research Center, Department of Neurology, University of California-Los Angeles, 710 Westwood Plaza Rm. 2-238, Los Angeles, CA 90095, USA. j.cummings@mednet.ucla.edu
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Cummings
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000150:complications* / Q000503:physiopathology*; D001921:Brain / Q000503:physiopathology*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005702:Galantamine / Q000627:therapeutic use*; D006801:Humans; D001523:Mental Disorders / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology*; D048448:Phenylcarbamates / Q000627:therapeutic use*; D015995:Prevalence; D000068836:Rivastigmine
chemical_list: D048448:Phenylcarbamates; D005702:Galantamine; D000068836:Rivastigmine